熱門資訊> 正文

enGene Holdings GAAP每股收益为2.29美元

2025-12-23 05:05

enGene Holdings press release (ENGN): FY GAAP EPS of $2.29.
Full Year Financial Results ended October 31, 2025Total operating expenses were $123.2 million for the full year ended October 31, 2025, compared to $62.3 million for 2024. Research and development expenses increased by $56.2 million, primarily driven by increased manufacturing, personnel and clinical costs related to our LEGEND trial and in preparation for our planned Biologics License Application submission in the second half of 2026.

More on enGene Holdings

enGene Holdings Inc. (ENGN) Discusses Preliminary Data From LEGEND Pivotal Cohort in High-Risk BCG-Unresponsive NMIBC - Slideshow
enGene Holdings: Still A Buy After A Massive Surge
enGene Holdings Inc. (ENGN) Discusses Preliminary Data From LEGEND Pivotal Cohort in High-Risk BCG-Unresponsive NMIBC Transcript
enGene announces proposed public offering
Seeking Alpha’s Quant Rating on enGene Holdings

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。